At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 437 enrolled
Drug / intervention
desvenlafaxine succinate sustained release +1 moredrug
Likely dose
desvenlafaxine succinate sustained release 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jan 16, 2009·Updated Mar 10, 2011
In Brief
A Phase 3 clinical trial evaluating desvenlafaxine succinate sustained release and Genotyping for Depressive Disorder, Major. Completed, enrolled 437 participants.
Detailed Summary
This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartFeb 2009
Primary CompletionOct 2009
Study CompletionNov 2009
TodayJul 2026
First PostedJan 16, 2009
Enrollment StartFeb 1, 2009
Primary CompletionOct 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.5 years ago
Interventions
desvenlafaxine succinate sustained releasedrug
50 mg/day oral tablet for 12 weeks
Genotypinggenetic
CYP2D6 genotyping at randomization